14244
document
Amisulpride versus bromocriptine in infantile autism : a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function . An alteration of dopaminergic ( DA ) function much more complex than simple hyperactivity has been evoked in infantile autism . We therefore compared the clinical efficacy of a DA antagonist ( amisulpride ) and a DA agonist ( bromocriptine ) in a randomized , double-blind , crossover trial in 9 children with autism , likely severely mentally retarded . Amisulpride acts preferentially on specific autistic symptoms whereas bromocriptine acts more on motor hyperactivity and attention symptoms . These findings raise the specificity of these two drugs which appear to act preferentially on some target symptoms and are consistent with some clinical and pharmacological observations showing a sedative effect with low doses of DA agonists and a stimulant effect with low doses of DA antagonists such as the benzamides .
14245
Intervention_Pharmacological
Amisulpride
14246
Intervention_Pharmacological
bromocriptine
14247
Intervention_Pharmacological
DA antagonist ( amisulpride )
14248
Intervention_Pharmacological
DA agonist ( bromocriptine )
14249
Intervention_Pharmacological
Amisulpride
14250
Intervention_Pharmacological
bromocriptine
14251
Intervention_Pharmacological
DA agonists
14252
Intervention_Pharmacological
DA antagonists
14253
Intervention_Pharmacological
benzamides
14254
Outcome_Physical
dopaminergic ( DA ) function
14255
Outcome_Other
clinical efficacy
14256
Outcome_Physical
motor hyperactivity and attention symptoms
14257
Outcome_Physical
sedative effect
14258
Outcome_Physical
stimulant effect
14259
Participant_Condition
infantile autism :
14260
Participant_Condition
infantile autism
14261
Participant_Sample-size
9
14262
Participant_Age
children
14263
Participant_Condition
autism
14264
Participant_Condition
mentally retarded